ORAGENICS INC

OGENNYSE AMERICAN

🏆 #4360 by market capEarnings Nov 16US Equity

$0.55▲ $0.00 (+0.16%)

Market closed · at close

1h—

24h▲ 0.2%

7d▲ 1.6%

14d▲ 2.3%

30d▼ 4.5%

1y▼ 52.7%

🏦Market Cap

$2M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

61.3%

High

💵FCF Margin

—

⚖️P/S Ratio

62.0x

Expensive

Otter Score

Fair

Trading Snapshot

Day Range: $0.54 – $0.55
52-Week Range: $0.48 – $1.45
Volume: $3.18B
Avg Volume: $2.51B
Shares Outstanding: 4.5M
Next Earnings: Sep 22, 2026

Fundamentals Snapshot

Annual Revenue: $39,862
Last Q Revenue: $10,096
P/E Ratio: —
P/S Ratio: 62.0x
EPS (TTM): $-5.61
Dividend Yield: —

Why Investors Own OGEN

✓High-growth profile — revenue up +54.8% YoY with expanding US Equity exposure.
✓Healthy economics — 49% gross margin and 20% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$39,862▲ +53.3% YoY

Gross Margin (TTM)

48.7%▲ +3.0% YoY

Operating Income (TTM)

$7,175▲ +53.3% YoY

Free Cash Flow (TTM)

$8,132▲ +53.3% YoY

About ORAGENICS INC

Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on creating treatments for infectious diseases. Among its pipeline assets are two vaccine candidates designed to combat the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2): NT-CoV2-1, an intranasal formulation, and Terra CoV-2, an intramuscular option. Beyond its infectious disease focus, Oragenics also has other experimental treatments under development, including LPT3-04, targeting weight loss, and SMaRT Replacement Therapy, a topical solution aimed at preventing dental cavities. Strategic alliances are also a part of its operations. This includes a licensing deal with Noachis Terra Inc. for patents and biological resources related to pre-fusion coronavirus spike proteins. Additionally, Oragenics is collaborating with Precigen, Inc. and ILH Holdings, Inc. on the advancement and market introduction of MU1140 and its associated compounds. Established in 1996, the company, formerly known as Oragen, Inc., maintains its headquarters in Tampa, Florida.

🦦